SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-029741
Filing Date
2020-02-10
Accepted
2020-02-10 16:01:47
Documents
16
Period of Report
2020-02-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d868460d8k.htm   iXBRL 8-K 33924
2 EX-99.1 d868460dex991.htm EX-99.1 13945
3 EX-99.2 d868460dex992.htm EX-99.2 373344
7 GRAPHIC g868460g0210115033693.jpg GRAPHIC 3544
8 GRAPHIC g868460g51r70.jpg GRAPHIC 136081
  Complete submission text file 0001193125-20-029741.txt   828903

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20200210.xsd EX-101.SCH 3068
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20200210_lab.xml EX-101.LAB 17375
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20200210_pre.xml EX-101.PRE 10952
17 EXTRACTED XBRL INSTANCE DOCUMENT d868460d8k_htm.xml XML 3238
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 20591851
SIC: 2834 Pharmaceutical Preparations